Cambridge Investment Research Advisors, Inc. Clearside Biomedical, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.9 Billion
- Q4 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 10,500 shares of CLSD stock, worth $9,450. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,500
Previous 10,500
-0.0%
Holding current value
$9,450
Previous $13,000
23.08%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding CLSD
# of Institutions
50Shares Held
11.6MCall Options Held
24KPut Options Held
12.1K-
Vanguard Group Inc Valley Forge, PA2.81MShares$2.53 Million0.0% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$1.98 Million3.43% of portfolio
-
Carmignac Gestion Paris, I01.93MShares$1.74 Million0.03% of portfolio
-
Black Rock Inc. New York, NY798KShares$718,3230.0% of portfolio
-
Geode Capital Management, LLC Boston, MA764KShares$687,6520.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $54.2M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...